ANG Lifesciences India (BOM:540694) Debt-to-Equity : N/A (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is ANG Lifesciences India Debt-to-Equity?

ANG Lifesciences India's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. ANG Lifesciences India's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. ANG Lifesciences India's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₹0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for ANG Lifesciences India's Debt-to-Equity or its related term are showing as below:

BOM:540694' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.55 Med: 0.84 Max: 4.55
Current: 0.84

During the past 11 years, the highest Debt-to-Equity Ratio of ANG Lifesciences India was 4.55. The lowest was 0.55. And the median was 0.84.

BOM:540694's Debt-to-Equity is ranked worse than
81.12% of 842 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs BOM:540694: 0.84

ANG Lifesciences India Debt-to-Equity Historical Data

The historical data trend for ANG Lifesciences India's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ANG Lifesciences India Debt-to-Equity Chart

ANG Lifesciences India Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

0.65

0.60

1.04

0.92

0.84

ANG Lifesciences India Quarterly Data
	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															N/A	0.84	N/A	0.84	N/A

Competitive Comparison of ANG Lifesciences India's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, ANG Lifesciences India's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ANG Lifesciences India's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ANG Lifesciences India's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where ANG Lifesciences India's Debt-to-Equity falls into.

ANG Lifesciences India Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

ANG Lifesciences India's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(499.481	+	228.409)	/	862.177
	=	0.84

ANG Lifesciences India's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0
	=	N/A

ANG Lifesciences India (BOM:540694) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

ANG Lifesciences India Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of ANG Lifesciences India's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

ANG Lifesciences India (BOM:540694) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ANG Lifesciences India Ltd (BOM:540694) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

Ranjit Avenue, B-Block, Darbara Complex, SCO 113, First Floor, District Shopping Complex, Amritsar, PB, IND, 143001

Website

https://www.anglifesciences.com

ANG Lifesciences India Ltd is an India-based engaged in the manufacturing of finished pharmaceutical formulations in the form of dry powder for injections. Geographically, the company carries out sales within India, as well as outside India; generating the majority of revenue from the sales of injections within India.

ANG Lifesciences India (BOM:540694) Headlines

No Headlines